AEterna Zentaris AEZS 1000% Chance !? (Seite 710)
eröffnet am 21.11.15 14:39:40 von
neuester Beitrag 18.04.23 19:48:47 von
neuester Beitrag 18.04.23 19:48:47 von
Beiträge: 9.063
ID: 1.221.897
ID: 1.221.897
Aufrufe heute: 3
Gesamt: 1.452.467
Gesamt: 1.452.467
Aktive User: 0
ISIN: CA0079756007 · WKN: A403TN · Symbol: ET80
7,2200
EUR
-2,17 %
-0,1600 EUR
Letzter Kurs 10:44:22 Tradegate
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 9,4960 | +126,18 | |
| 3,2000 | +93,94 | |
| 1,3300 | +30,51 | |
| 1,9800 | +26,11 | |
| 1,4700 | +23,01 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 7,9100 | -16,03 | |
| 7,5000 | -20,97 | |
| 2,4820 | -21,46 | |
| 0,6800 | -22,73 | |
| 4,1140 | -69,77 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 51.529.968 von jhackel am 19.01.16 17:56:56
5
Mehr als Predigen können wir nicht .. ..
5
Mehr als Predigen können wir nicht .. ..
Antwort auf Beitrag Nr.: 51.529.935 von herrscher2 am 19.01.16 17:54:12Give 5 
Kapieren halt manche noch nicht wofür diese Hüpfer da sind.
Kapieren halt manche noch nicht wofür diese Hüpfer da sind.
Herrlich 
Gratulation an meinen Broker und (Herr Scher)
Haben den CFD B Underlying short punkt genau gesetzt. Jetzt kann es Richtung 2 Dollar oder tiefer gehen. Börse (AE) ist doch so einfach .. ..
Io
Gratulation an meinen Broker und (Herr Scher)
Haben den CFD B Underlying short punkt genau gesetzt. Jetzt kann es Richtung 2 Dollar oder tiefer gehen. Börse (AE) ist doch so einfach .. ..
Io
Antwort auf Beitrag Nr.: 51.529.614 von lunatics am 19.01.16 17:25:19klingt ja gut, aber so richtig mag man daran nicht glauben. in USA gehts schon wieder rückwärts!
Aeterna Zentaris Concludes Successful Meeting of Clinical Investigators for Confirmatory Phase 3 Trial of Macrilen™
Aeterna Zentaris Inc. announced today that it concluded a successful meeting of the clinical investigators for the confirmatory Phase 3 trial of Macrilen™ (macimorelin), a novel orally-active ghrelin agonist for use in evaluating adult growth hormone deficiency (“AGHD”). As a result, the Company is confident that it will complete the confirmatory trial by year-end 2016.
Dr. Richard Sachse, the Company’s Chief Scientific Officer stated, “On January 16, we held an Investigators’ Meeting for our multi-center confirmatory Phase 3 clinical trial of Macrilen™. The purpose of the meeting was to review Macrilen™ with the investigators, as well as the clinical trial protocol. The 77 investigators and site personnel who attended the meeting included Jose Manuel Garcia, MD, PhD, Associate Professor of Medicine at University of Washington School of Medicine, Seattle, who is serving as coordinating investigator. Dr. Garcia expressed his commitment to the development of Macrilen™ because of the medical need for such a convenient test in the absence of an FDA-approved diagnostic test for AGHD.”
Patients who are believed to have AGHD are now very often evaluated by means of the insulin tolerance test (“ITT”). The ITT is the historical gold standard for the evaluation of AGHD because of its high sensitivity and specificity. However, the ITT is inconvenient to the patients and physicians and contra-indicated in certain patients, such as patients with coronary heart disease or seizure disorder, because it requires the patient to experience hypoglycemia to obtain a result. Some physicians will not induce full hypoglycemia, intentionally compromising accuracy to increase safety and comfort for the patient. Furthermore, administration of the ITT is expensive because the patient must be constantly monitored by a physician for the 2-4 hour duration of the test and the test must be administered in a setting where emergency equipment is available and where the patient may be quickly hospitalized. The ITT is not used for patients with co-morbidities, such as CV, seizure disorder or a history of brain cancer or for patients who are elderly and frail, due to safety concerns.
The Company believes that Macrilen™, if it is approved, is likely to be rapidly adopted by physicians as the preferred means of evaluating AGHD for the following reasons:
it is safer than the ITT because it does not require the patient to become hypoglycemic;
Macrilen™ is administered orally, while the ITT requires an intravenous infusion of insulin;
the evaluation of AGHD using Macrilen™ is much less time consuming and labor intensive than the ITT and, therefore, it is less expensive to conduct; and
the evaluation can be conducted in the physician’s office rather than in a hospital setting.
http://finance.yahoo.com/news/aeterna-zentaris-concludes-suc…
Aeterna Zentaris Inc. announced today that it concluded a successful meeting of the clinical investigators for the confirmatory Phase 3 trial of Macrilen™ (macimorelin), a novel orally-active ghrelin agonist for use in evaluating adult growth hormone deficiency (“AGHD”). As a result, the Company is confident that it will complete the confirmatory trial by year-end 2016.
Dr. Richard Sachse, the Company’s Chief Scientific Officer stated, “On January 16, we held an Investigators’ Meeting for our multi-center confirmatory Phase 3 clinical trial of Macrilen™. The purpose of the meeting was to review Macrilen™ with the investigators, as well as the clinical trial protocol. The 77 investigators and site personnel who attended the meeting included Jose Manuel Garcia, MD, PhD, Associate Professor of Medicine at University of Washington School of Medicine, Seattle, who is serving as coordinating investigator. Dr. Garcia expressed his commitment to the development of Macrilen™ because of the medical need for such a convenient test in the absence of an FDA-approved diagnostic test for AGHD.”
Patients who are believed to have AGHD are now very often evaluated by means of the insulin tolerance test (“ITT”). The ITT is the historical gold standard for the evaluation of AGHD because of its high sensitivity and specificity. However, the ITT is inconvenient to the patients and physicians and contra-indicated in certain patients, such as patients with coronary heart disease or seizure disorder, because it requires the patient to experience hypoglycemia to obtain a result. Some physicians will not induce full hypoglycemia, intentionally compromising accuracy to increase safety and comfort for the patient. Furthermore, administration of the ITT is expensive because the patient must be constantly monitored by a physician for the 2-4 hour duration of the test and the test must be administered in a setting where emergency equipment is available and where the patient may be quickly hospitalized. The ITT is not used for patients with co-morbidities, such as CV, seizure disorder or a history of brain cancer or for patients who are elderly and frail, due to safety concerns.
The Company believes that Macrilen™, if it is approved, is likely to be rapidly adopted by physicians as the preferred means of evaluating AGHD for the following reasons:
it is safer than the ITT because it does not require the patient to become hypoglycemic;
Macrilen™ is administered orally, while the ITT requires an intravenous infusion of insulin;
the evaluation of AGHD using Macrilen™ is much less time consuming and labor intensive than the ITT and, therefore, it is less expensive to conduct; and
the evaluation can be conducted in the physician’s office rather than in a hospital setting.
http://finance.yahoo.com/news/aeterna-zentaris-concludes-suc…
Trading Spotlight
Antwort auf Beitrag Nr.: 51.509.277 von lunatics am 16.01.16 16:13:33
sooooo gefällts natürlich.
Jetzt kommt die Kohle..... Schade haben's einige hier nicht begriffen...
Zitat von lunatics: ...Ich denke, dass wir nächste Woche wieder locker über USD 3 stehen
sooooo gefällts natürlich.
Jetzt kommt die Kohle..... Schade haben's einige hier nicht begriffen...
Antwort auf Beitrag Nr.: 51.529.356 von 1Fuchs am 19.01.16 17:02:30Wieso? Du verstehst halt das Spiel noch nicht. Wer beim letzten Up um die 5.5 shortete, liegt immer noch im Gewinn. Wer dazu noch eine Weihnachtsgratifikation bekommt, kann sie heute zu guten Kursen verkaufen. Auf das Management ist halt Verlass.
Und da wir ja bei der Aktienzahl sind, 7 Mio. in 2 Stunden verkauft. Meines Wissens haben die um die 10 Mio. Aktien. Woher kommen denn so viele Aktien hä? Warte nur mal die nächsten Tage ab. Die Hochs werden immer niedriger.
Und da wir ja bei der Aktienzahl sind, 7 Mio. in 2 Stunden verkauft. Meines Wissens haben die um die 10 Mio. Aktien. Woher kommen denn so viele Aktien hä? Warte nur mal die nächsten Tage ab. Die Hochs werden immer niedriger.
Antwort auf Beitrag Nr.: 51.529.284 von R32 am 19.01.16 16:54:49Wer da 7 Mio shares in nicht mal 2 Stunden kauft. Bestimmt nur Kleinanleger. Ich relaxe und amusiere mich über Hackel den Obershorter.
Antwort auf Beitrag Nr.: 51.529.098 von jhackel am 19.01.16 16:36:17Ist der Herr Scher nicht short ? Wär ja der Hammer
Antwort auf Beitrag Nr.: 51.497.469 von jhackel am 15.01.16 08:53:01
Ich liebe das Management. Die Shorter können die Weihnachtsgratifikation zu guten Kursen loswerden.
Zitat von jhackel: @ herrscher,
hast du auch plötzlich ein neues Kontingent bekommen?
Ist wohl eine nachträgliche Weihnachts-Gratifikation weil das letzte Jahr so gut gelaufen ist.
Können sie verticken und zählt auch nicht zu den Kontingenten, die man zurückkaufen muss.
Ich liebe das Management. Die Shorter können die Weihnachtsgratifikation zu guten Kursen loswerden.
Durchsuchen
